NPCE Overview

NeuroPace, Inc. is a medical device company. The Company is focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated RNS System is a brain-responsive platform that delivers personalized, real-time treatment at the seizure source. The Company has developed its RNS System to address the individualized nature of drug-resistant epilepsy and deliver a safe therapy for focal onset seizures anywhere in the brain. The RNS System is a device that records brain activity data and allows clinicians to monitor patients not only in person, but also remotely. The RNS System monitors and analyzes the brain’s electrical activity, recognizes patient-specific abnormal patterns, and delivers treatment at the seizure source. The Company’s RNS System is also engaged in treating other brain disorders, including depression, impulse control disorders, memory disorders, and post-traumatic stress disorders.

Wall Street analysts forecast NPCE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for NPCE is19.17 USD with a low forecast of 16.00 USD and a high forecast of 22.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Neuropace Inc revenue for the last quarter amounts to 26.59M USD, increased 23.86

Neuropace Inc. EPS for the last quarter amounts to -0.08 USD, decreased -55.56

Neuropace Inc (NPCE) has 184 emplpoyees as of March 04 2026.

Today NPCE has the market capitalization of 460.65M USD.